Effect of calcium channel blockers on platelet GPIIb-IIIa as a calcium channel in liposomes: comparison with effects on the intact platelet
- PMID: 1319614
Effect of calcium channel blockers on platelet GPIIb-IIIa as a calcium channel in liposomes: comparison with effects on the intact platelet
Abstract
The platelet membrane glycoprotein IIb-IIIa complex is essential for platelet aggregation and functions as a fibrinogen receptor on the activated platelet. When incorporated into phospholipid vesicles, this glycoprotein complex can function as an apparent calcium channel which facilitates the transit of calcium across a phospholipid barrier. In order to further evaluate this calcium channel, the effect of calcium channel blockers of the dihydropyridine (nifedipine and nicardipine), arylalkylamine (verapamil) and benzothiazepine (diltiazem) classes were evaluated on GPIIb-IIIa liposomes with encapsulated fura-2 (a fluorescent calcium indicator). Nicardipine, verapamil, and nifedipine significantly inhibited calcium influx into GPIIb-IIIa liposomes; however, this required 190 microM, 400 microM, and 140 microM drug, respectively. These concentrations are 10-1,000 fold greater than those clinically obtainable. In contrast, diltiazem at concentrations greater than 220 microM and amiloride at concentrations greater than 800 microM showed no inhibitory effects. When aspirinized platelets were activated with 30 micrograms/ml bovine fibrillar collagen, both nicardipine and diltiazem produced a decrease in both the initial rise and maximum cytoplasmic calcium concentration. Parallel experiments were performed to assess the effects of verapamil, nicardipine, and diltiazem on platelet aggregation in platelet rich plasma. Nicardipine, 190-380 microM, induced a prolongation of the lag phase, but no effect on the final degree of platelet aggregation to collagen. Similar inhibition of platelet aggregation was seen with diltiazem and verapamil although the effect of diltiazem was less pronounced particularly at higher concentrations of collagen. No effect was seen on aggregation with 32 microM ADP which is release independent, or on the primary wave of low dose ADP induced platelet aggregation.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.Circ Res. 1983 Feb;52(2 Pt 2):I115-9. Circ Res. 1983. PMID: 6831645
-
Glycoproteins IIb and IIIa and platelet thrombospondin in a liposome model of platelet aggregation.Thromb Haemost. 1986 Apr 30;55(2):240-5. Thromb Haemost. 1986. PMID: 2940724
-
Influence of calcium antagonists on platelet function and vascular prostacyclin production.Blood Press Suppl. 1994;1:75-80. Blood Press Suppl. 1994. PMID: 8205307
-
Influence of calcium-channel blockers on platelet function and arachidonic acid metabolism.Am J Cardiol. 1985 Jan 25;55(3):158B-164B. doi: 10.1016/0002-9149(85)90626-5. Am J Cardiol. 1985. PMID: 2982252 Review.
-
Calcium Channel Blockers.2017 Jan 11. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Jan 11. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643892 Free Books & Documents. Review.
Cited by
-
Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty.Postgrad Med J. 2003 Sep;79(935):522-6. doi: 10.1136/pmj.79.935.522. Postgrad Med J. 2003. PMID: 13679549 Free PMC article. Clinical Trial.
-
Calcium channel antagonists in the modern era of coronary thrombolysis: benefit or detriment?Cardiovasc Drugs Ther. 1996 Sep;10(4):403-7. doi: 10.1007/BF00051103. Cardiovasc Drugs Ther. 1996. PMID: 8924052